NSPX DD Package: 1. Company Profile: Inspyr Th
Post# of 103024
(Total Views: 1022)
Posted On: 01/06/2019 8:09:45 PM
NSPX DD Package:
1. Company Profile:
Inspyr Therapeutics, Inc., formerly Genspera, Inc is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark Pharmaceuticals, Inc., Inspyr has a proprietary, industry-leading adenosine receptor modulator (ARM) technology platform and a broad pipeline of novel therapies. Inspyr’s pipeline includes Mipsagargin, a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases. The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.
2. MIPSAGARGIN- Inspyr’s drug that can potentially cure various cancers-
MUST WATCH videos about Mipsagargin:
Intro into Mipsagargin by Inspyr(formerly Genspera):
be.com/watch?time_continue=4&v=HMasGEnMysA
NSPX in the News- Mipsagargin Breakthrough Drug- Potential replacement for chemotherapy:
be.com/watch?feature=youtu.be&v=fIgp4n3Itzo
Physicians React to Phase 2 Update on GenSpera’s Mipsagargin in Hepatocellular Carcinoma at ASCO GI:
https://m.youtube.com/watch?v=4lTX7y16pt0
Mipsagargin latest update as of June 2018 (with other patent info):
https://adisinsight.springer.com/drugs/800030883
https://patents.justia.com/assignee/inspyr-therapeutics-inc
Q/A with the Doctor behind Mipsagargin:
https://www.reddit.com/r/IAmA/comments/3gqfnn...scientist/
3. Meet our CEO- Chris Lowe:
https://m.youtube.com/watch?v=LIfsnZP6W2o
Chris Lowe joined FLG in 2014, serves on the Firm’s Management Committee and was elected Co-Managing Partner in 2018. Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies. Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees. Chris helps companies succeed by assisting them with corporate and financial strategy, including early stage financing, successive fundraising and IPOs, public company advising and Wall Street communications, licensing transactions, M&A, restructurings and coaching at every level of the C-Suite. In particular, he excels at helping companies navigate the challenges of accessing capital, M&A, licensing, restructurings and exits.
During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies, and has overseen three SOX-404 implementations. As VP and CAO, he drove a parallel M&A and IPO path resulting in the sale of Peninsula Pharmaceuticals to Johnson & Johnson for over $300M in 2005, including the design of a tax efficient spinout for assets which were undervalued by Johnson & Johnson. As CFO of Asthmatx, a medical technology company, he actively drove strategic supply negotiations and led the parallel M&A and IPO process resulting in a $50M strategic investment from Olympus Medical and ultimately the sale of the company to Boston Scientific in a deal valued at approximately $400M. As its Chief Financial Officer, he also took Anthera Pharmaceuticals, a pharmaceutical development company, public in 2010 during the height of the financial crisis, raising over $300M in both the private and public markets during his tenure.
Prior to joining FLG, Chris recently served as a strategy, financial and management consultant to several public and private companies, assisting them with financings, market due diligence, Wall Street communications, and exits.
Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University. Chris currently sits on the Board of Directors of the following public and private companies: Hansen Medical (NASDAQ: HNSN; 2006-present); Pacific Pharmaceuticals (private; 2010-present); and Career Closet (Non Profit; 2009-present).
4. Most recent NEWS with potential 12 Million Licensing deal with Ridgeway Therapeutics:
Inspyr to License Oncology Related Compounds to Ridgeway Therapeutics Inc.
9/17/18, 8:00 AM
WESTLAKE VILLAGE, Calif., Sept. 17, 2018 Inspyr Therapeutics announced today that it has entered into an agreement with Ridgeway Therapeutics Inc. in which Ridgeway will license and assume control of certain assets relating to Inspyr's oncology development programs, including intellectual property rights relating to adenosine antagonists owned by Inspyr.
Adenosine receptors have a variety of functions in the body that are expressed through four subtypes (A1, A2A, A2B, and A3). The adenosine A2 receptor subtypes (A2R) are of particular interest as potential targets for the treatment of cancer. Extremely high levels of adenosine are found locally in the tumor microenvironment. These have a direct immunosuppressive effect on T-cells and other cell types that would otherwise attack and kill cancer cells. Inhibition of the A2R has the potential to reverse these immunosuppressive effects.
Inspyr and Ridgeway will collaborate on certain aspects of development which will include a minimum level of purchased services by Ridgeway within 18 months of this transaction. In addition, Inspyr is eligible for approximately $12 million in success-based milestones from the Transaction. Inspyr is also entitled to receive royalties on all commercial sales. In the event Ridgeway sub-licenses these assets, Inspyr is entitled to share in the proceeds of any future transaction.
https://www.prweb.com/releases/inspyr_to_lice...761201.htm
***This licensing deal does not cover Mipsagargin so there may be another separate deal in the works....
5. Past News Releases or Articles of Significance:
1. Oct 23 2017- Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
https://globenewswire.com/news-release/2017/1...ealth.html
2. Oct 4 2017- Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital-Dr. Allison Reiss Initiates Pre-Clinical Study for Atherosclerosis
https://globenewswire.com/news-release/2017/1...pital.html
3. Oct 2 2017- Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine-Dr. Cirle Warren Initiates Pre-Clinical Study for Clostridium Difficile
https://globenewswire.com/news-release/2017/1...icine.html
4. Sept 13 2017- Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger- Creating Integrated Company with Proprietary Platform, Broad Pipeline, and Significant Drug Development Expertise
https://globenewswire.com/news-release/2017/0...erger.html
5. Sept 12 2017- Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures
https://globenewswire.com/news-release/2017/0...tures.html
6. Aug 4 2016- Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
https://www.businesswire.com/news/home/201608...-Executive
7. Aug 1 2016- GenSpera Announces Name Change to Inspyr Therapeutics[b/]
https://www.businesswire.com/news/home/201608...erapeutics
8. June 9 2015- GenSpera And Cancer-Specific Hand Grenades
https://seekingalpha.com/article/3245765-gens...d-grenades
9. March 30 2015- GenSpera Contends In The Prodrug Space, Reaching Phase 3
https://seekingalpha.com/article/3039246-gens...ng-phase-3
10. Feb 24 2015 - Genspera's Mipsagargin Phase 2 Results Impress
https://seekingalpha.com/article/2944176-gens...ts-impress
11. Jan 16 2015- ***GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin-First-in-Class Agent is Well Tolerated in Liver Cancer Patients***
https://www.prnewswire.com/news-releases/gens...21471.html
6. Recent Inside significant stake by Hedge Fund Sabby Management:
NEW 13G Filing:
https://www.otcmarkets.com/filing/html?id=130...p-vXMxZ1yh
Sabby Management, LLC is an employee owned investment manager. The firm primarily provides its services to pooled investment vehicles. It invests in the public equity and alternative investment markets of the United States. The firm primarily invests in options. It also makes private investments in public equity. The firm employs a opportunistic and event-driven strategy to make its investments. It also employs fundamental and quantitative analysis. The firm invests in the healthcare sector, including the biotechnology and pharmaceutical sector. Sabby Management, LLC was formed on June 6, 2011 and is based in Upper Saddle River, New Jersey.
7. Share Structure:
O/S= 46,858,929 As of November 26,2018
A/S=150,000,000 As of November 26,2018
1. Company Profile:
Inspyr Therapeutics, Inc., formerly Genspera, Inc is an integrated biopharmaceutical company focused on the development of novel therapies to treat cancer, inflammation, and other serious diseases. Through a merger with Lewis and Clark Pharmaceuticals, Inc., Inspyr has a proprietary, industry-leading adenosine receptor modulator (ARM) technology platform and a broad pipeline of novel therapies. Inspyr’s pipeline includes Mipsagargin, a pro-drug that has completed a phase 2 clinical trial for the treatment of liver cancer, and the ARM preclinical programs consisting of A2A, A2B, and dual A2A/A2B receptor antagonists for the treatment of cancer and A2A agonists for the treatment of inflammatory and other serious diseases. The Company has fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia, where a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.
2. MIPSAGARGIN- Inspyr’s drug that can potentially cure various cancers-
MUST WATCH videos about Mipsagargin:
Intro into Mipsagargin by Inspyr(formerly Genspera):
be.com/watch?time_continue=4&v=HMasGEnMysA
NSPX in the News- Mipsagargin Breakthrough Drug- Potential replacement for chemotherapy:
be.com/watch?feature=youtu.be&v=fIgp4n3Itzo
Physicians React to Phase 2 Update on GenSpera’s Mipsagargin in Hepatocellular Carcinoma at ASCO GI:
https://m.youtube.com/watch?v=4lTX7y16pt0
Mipsagargin latest update as of June 2018 (with other patent info):
https://adisinsight.springer.com/drugs/800030883
https://patents.justia.com/assignee/inspyr-therapeutics-inc
Q/A with the Doctor behind Mipsagargin:
https://www.reddit.com/r/IAmA/comments/3gqfnn...scientist/
3. Meet our CEO- Chris Lowe:
https://m.youtube.com/watch?v=LIfsnZP6W2o
Chris Lowe joined FLG in 2014, serves on the Firm’s Management Committee and was elected Co-Managing Partner in 2018. Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies. Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees. Chris helps companies succeed by assisting them with corporate and financial strategy, including early stage financing, successive fundraising and IPOs, public company advising and Wall Street communications, licensing transactions, M&A, restructurings and coaching at every level of the C-Suite. In particular, he excels at helping companies navigate the challenges of accessing capital, M&A, licensing, restructurings and exits.
During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies, and has overseen three SOX-404 implementations. As VP and CAO, he drove a parallel M&A and IPO path resulting in the sale of Peninsula Pharmaceuticals to Johnson & Johnson for over $300M in 2005, including the design of a tax efficient spinout for assets which were undervalued by Johnson & Johnson. As CFO of Asthmatx, a medical technology company, he actively drove strategic supply negotiations and led the parallel M&A and IPO process resulting in a $50M strategic investment from Olympus Medical and ultimately the sale of the company to Boston Scientific in a deal valued at approximately $400M. As its Chief Financial Officer, he also took Anthera Pharmaceuticals, a pharmaceutical development company, public in 2010 during the height of the financial crisis, raising over $300M in both the private and public markets during his tenure.
Prior to joining FLG, Chris recently served as a strategy, financial and management consultant to several public and private companies, assisting them with financings, market due diligence, Wall Street communications, and exits.
Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University. Chris currently sits on the Board of Directors of the following public and private companies: Hansen Medical (NASDAQ: HNSN; 2006-present); Pacific Pharmaceuticals (private; 2010-present); and Career Closet (Non Profit; 2009-present).
4. Most recent NEWS with potential 12 Million Licensing deal with Ridgeway Therapeutics:
Inspyr to License Oncology Related Compounds to Ridgeway Therapeutics Inc.
9/17/18, 8:00 AM
WESTLAKE VILLAGE, Calif., Sept. 17, 2018 Inspyr Therapeutics announced today that it has entered into an agreement with Ridgeway Therapeutics Inc. in which Ridgeway will license and assume control of certain assets relating to Inspyr's oncology development programs, including intellectual property rights relating to adenosine antagonists owned by Inspyr.
Adenosine receptors have a variety of functions in the body that are expressed through four subtypes (A1, A2A, A2B, and A3). The adenosine A2 receptor subtypes (A2R) are of particular interest as potential targets for the treatment of cancer. Extremely high levels of adenosine are found locally in the tumor microenvironment. These have a direct immunosuppressive effect on T-cells and other cell types that would otherwise attack and kill cancer cells. Inhibition of the A2R has the potential to reverse these immunosuppressive effects.
Inspyr and Ridgeway will collaborate on certain aspects of development which will include a minimum level of purchased services by Ridgeway within 18 months of this transaction. In addition, Inspyr is eligible for approximately $12 million in success-based milestones from the Transaction. Inspyr is also entitled to receive royalties on all commercial sales. In the event Ridgeway sub-licenses these assets, Inspyr is entitled to share in the proceeds of any future transaction.
https://www.prweb.com/releases/inspyr_to_lice...761201.htm
***This licensing deal does not cover Mipsagargin so there may be another separate deal in the works....
5. Past News Releases or Articles of Significance:
1. Oct 23 2017- Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
https://globenewswire.com/news-release/2017/1...ealth.html
2. Oct 4 2017- Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital-Dr. Allison Reiss Initiates Pre-Clinical Study for Atherosclerosis
https://globenewswire.com/news-release/2017/1...pital.html
3. Oct 2 2017- Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine-Dr. Cirle Warren Initiates Pre-Clinical Study for Clostridium Difficile
https://globenewswire.com/news-release/2017/1...icine.html
4. Sept 13 2017- Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger- Creating Integrated Company with Proprietary Platform, Broad Pipeline, and Significant Drug Development Expertise
https://globenewswire.com/news-release/2017/0...erger.html
5. Sept 12 2017- Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures
https://globenewswire.com/news-release/2017/0...tures.html
6. Aug 4 2016- Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
https://www.businesswire.com/news/home/201608...-Executive
7. Aug 1 2016- GenSpera Announces Name Change to Inspyr Therapeutics[b/]
https://www.businesswire.com/news/home/201608...erapeutics
8. June 9 2015- GenSpera And Cancer-Specific Hand Grenades
https://seekingalpha.com/article/3245765-gens...d-grenades
9. March 30 2015- GenSpera Contends In The Prodrug Space, Reaching Phase 3
https://seekingalpha.com/article/3039246-gens...ng-phase-3
10. Feb 24 2015 - Genspera's Mipsagargin Phase 2 Results Impress
https://seekingalpha.com/article/2944176-gens...ts-impress
11. Jan 16 2015- ***GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin-First-in-Class Agent is Well Tolerated in Liver Cancer Patients***
https://www.prnewswire.com/news-releases/gens...21471.html
6. Recent Inside significant stake by Hedge Fund Sabby Management:
NEW 13G Filing:
https://www.otcmarkets.com/filing/html?id=130...p-vXMxZ1yh
Sabby Management, LLC is an employee owned investment manager. The firm primarily provides its services to pooled investment vehicles. It invests in the public equity and alternative investment markets of the United States. The firm primarily invests in options. It also makes private investments in public equity. The firm employs a opportunistic and event-driven strategy to make its investments. It also employs fundamental and quantitative analysis. The firm invests in the healthcare sector, including the biotechnology and pharmaceutical sector. Sabby Management, LLC was formed on June 6, 2011 and is based in Upper Saddle River, New Jersey.
7. Share Structure:
O/S= 46,858,929 As of November 26,2018
A/S=150,000,000 As of November 26,2018
(0)
(0)Scroll down for more posts ▼